Skip to main content
. 2022 Nov 11;14(11):2499. doi: 10.3390/v14112499

Figure 1.

Figure 1

Study design and the Dinucleotide distribution across VOCs at the lineage and clinical outcome level. (A) the steps highlight the sample distribution across Alpha, Delta, and Omicron, sequencing data processing, and downstream analysis of the significant mutations. (B) AT/U and GC distribution in the genomes of the Alpha, Delta, and Omicron samples included in the study. (C) AT/U and GC distribution across the clinical outcomes with VOCs infection—DR, DM, OR, and OM.